EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition - AstraZeneca (NASDAQ:AZN)

AstraZeneca buys European cell therapy company

Today's biotech news update includes Orca Bio's T cell therapy, RFK Jr.’s regenerative medicine meeting, and an AstraZeneca acquisition.

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and autoimmune conditions.

The start-up of Mont-Saint-Guibert will become a wholly owned subsidiary of AstraZeneca, with activities in Belgium. Several Walloon investors are in the capital of EsoBiotec. ...

EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition - AstraZeneca (NASDAQ:AZN)

MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN). The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to t…

AstraZeneca's $1 Billion Deal Highlights Growing Interest in In Vivo Cell Therapies – RamaOnHealthcare

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.AstraZeneca is buying EsoBiotec for up to $1 billion for the company’s in vivo CAR-T cell drugs, or therapies that reprogram immune cells directly within patients' bodies. Analysts say the deal highlights the pharma [...]

AstraZeneca's $1 Billion Deal Highlights Growing Interest in In Vivo Cell Therapies

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.